All News

Opdivo plus Yervoy in the neoadjuvant setting reduced the risk for recurrence, progression or death, potentially offering patients with stage 3 melanoma a new standard of care.

Tagrisso following chemoradiotherapy improved progression-free survival compared with placebo in stage 3 EGFR-mutated non–small cell lung cancer.

Researchers found that adding retroperitoneal lymphadenectomy to cytoreductive surgery did not improve survival among patients with advanced ovarian cancer.

Researchers found telehealth care to deliver comparable quality-of-life benefits versus in-person visits among patients with advanced non-small cell lung cancer.

For the first time in decades, a new regimen — consolidation Imfinzi after chemoradiation — improved outcomes in patients with limited-stage small cell lung cancer.

Rybrevant plus Leclaza had promising response and progression-free survival rates in patients with EGFR-mutant non-small cell lung cancer.

Eight-year follow-up showed that Tafinlar plus Mekinist continued to improve outcomes for patients with stage 3 melanoma.

Rybrevant plus Leclaza outperformed Tagrisso regarding progression-free survival in patients with EGFR-mutant non-small cell lung cancer.

An Adcetris-based treatment regimen improved progression-free survival and was more tolerable for patients with classical Hodgkin lymphoma.

Lorbrena demonstrated longer progression-free survival and improved time to intracranial progression, compared with Xalkori in ALK-positive non-small cell lung cancer.

From NBA Hall of Famer Bill Walton dying from cancer to an ancient skull showing evidence of early cancer treatments, here’s what’s happening in the oncology space this week.

Scemblix outperformed standard tyrosine kinase inhibitor treatment in patients with Philadelphia chromosome-positive chronic myeloid leukemia.

The priority review is based on findings from a study that found that inavolisib reduced the risk for disease progression or death by 57%.

After I had surgery for my colon cancer, I started taking better care of myself, starting with regaining weight.

The CAR-T cell therapy, Breyanzi, has received FDA approval for relapsed or refractory mantle cell lymphoma.

Compared to open hemihepatectomy, the laparoscopic approach resulted in faster recovery time and higher quality of life, researchers found.

I expected chemotherapy, radiation and surgery to be difficult, but I felt totally lost after treatment ended.

As someone with follicular lymphoma, I joined a cancer advocacy group, but it wasn't what I was expecting.

Retevmo was approved for childhood metastatic medullary thyroid, thyroid and solid tumors with RET mutations or gene fusions.

Sarclisa was granted a priority review by the Food and Drug Administration for patients newly diagnosed with multiple myeloma who are ineligible for blood transplants.

Curing childhood cancer, any kind, is no place to be divided.

I’m grateful for my medical background and how it helped me care for my mom after her cancer diagnosis.

Patients aged 80 and older are often excluded from receiving the standard regimen for acute myeloid leukemia. However, research showed that some patients can tolerate the therapy.

During my time with cancer, I've come across words associated with cancer that I don't like and some that I appreciate.

Treatment with Pluvicto following ARPI resulted in favorable progression and response outcomes in PSMA-positive mCRPR.

Caregivers are tailor-made to help patients and survivors through their cancer experiences.

Here’s a look at therapies the FDA approved in the blood cancer space over the last few months.

I’ve experienced mixed emotions during my periods of remission for my myelodysplastic syndrome.